OEB071
Total Payments
$198,313
Transactions
4
Doctors
0
Companies
1
Payment Trends by Year
| Year | Amount | Transactions | Doctors |
|---|---|---|---|
| 2019 | $109,255 | 1 | 0 |
| 2018 | $1,109 | 1 | 0 |
| 2017 | $87,950 | 2 | 0 |
Payments by Nature
| Nature of Payment | Amount | Transactions | Share |
|---|---|---|---|
| Unspecified | $198,313 | 4 | 100.0% |
Research Studies & Clinical Trials
| Study Name | Sponsor | Amount | Doctors |
|---|---|---|---|
| PHASE IB TRIAL OF AEB071 A PKC INHIBITOR IN COMBINATION WITH BYL719 A PI3 INHIBITOR IN PATIENTS WITH METASTATIC UVEAL MELANOMA | Novartis Pharmaceuticals Corporation | $194,651 | 0 |
| AN OPEN LABEL SINGLE ARM PHASE 1B AND OR II STUDY OF AEB071 A PROTEIN KINASE C INHIBITOR AND EVEROLIMUS MTOR INHIBITOR IN PATIENTS WITH CD79 MUTANT OR ABC SUBTYPE DIFFUSE LARGE B CELL LYMPHOMA | Novartis Pharmaceuticals Corporation | $3,663 | 0 |
Top Doctors Receiving Payments for OEB071
| Doctor | Specialty | Location | Total | Records |
|---|---|---|---|---|
| Unknown | — | Fort Lee, NJ | $198,313 | 4 |
Ad
Manufacturing Companies
- Novartis Pharmaceuticals Corporation $198,313
Product Information
- Type Drug
- Total Payments $198,313
- Total Doctors 0
- Transactions 4
About OEB071
OEB071 is a drug associated with $198,313 in payments to 0 healthcare providers, recorded across 4 transactions in the CMS Open Payments database. The primary manufacturer is Novartis Pharmaceuticals Corporation.
Payment data is available from 2017 to 2019. In 2019, $109,255 was paid across 1 transactions to 0 doctors.
The most common payment nature for OEB071 is "Unspecified" ($198,313, 100.0% of total).
OEB071 is associated with 2 research studies, including "PHASE IB TRIAL OF AEB071 A PKC INHIBITOR IN COMBINATION WITH BYL719 A PI3 INHIBITOR IN PATIENTS WITH METASTATIC UVEAL MELANOMA" ($194,651).